Do Accelerated Approval Pathways Mean Earlier Patient Access?
Executive Summary
Accelerated access mechanisms that aim to get medicines to the market more quickly do not necessarily mean earlier access for patients, according to interim findings from a London School of Economics study.
You may also be interested in...
Mexico Continues Reliance Strategy To Expand Drug Access
Mexico aims to speed up the registration of generics and biosimilars.
Belgium Aims To Drive Biologic Competition Through Tendering
New tendering rules in Belgium aim to improve competition between biosimilars and originators, for example by setting contract durations for tendering contracts and limiting the criteria for such contracts.
Companies Need EU Funding To Cover ‘Enormous Expenditure’ Of Complying With Revised GMP Rules
Important updates to good manufacturing practice guidelines are likely to mean medicine shortages, warns a German pharmaceutical industry group.